AR121437A1 - Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético - Google Patents
Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acéticoInfo
- Publication number
- AR121437A1 AR121437A1 ARP210100495A ARP210100495A AR121437A1 AR 121437 A1 AR121437 A1 AR 121437A1 AR P210100495 A ARP210100495 A AR P210100495A AR P210100495 A ARP210100495 A AR P210100495A AR 121437 A1 AR121437 A1 AR 121437A1
- Authority
- AR
- Argentina
- Prior art keywords
- solvate
- potassium salt
- letermovir
- quinazolin
- piperazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proveen una sal de potasio y solvatos cristalinos de Letermovir, un método para su preparación, composición farmacéutica que comprende a la sal o al solvato y el uso de los mismos para el tratamiento de infecciones por citomegalovirus humano (HCMV). Reivindicación 1: Una sal de potasio cristalina de letermovir (2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acetato de potasio) de fórmula (1) o un solvato de la misma. Reivindicación 3: La sal de potasio cristalina de letermovir o el solvato de la misma de acuerdo con la reivindicación 1 ó 2, en donde el solvato es un 2,5 hidrato. Reivindicación 4: La sal de potasio cristalina de letermovir o el solvato de la misma de acuerdo con la reivindicación 1, en donde el solvato es un solvato mixto de agua y etanol. Reivindicación 5: La sal de potasio cristalina de letermovir o el solvato de la misma de acuerdo con la reivindicación 3, en donde dicho 2,5 hidrato se caracteriza porque muestra picos característicos en aproximadamente 6,1, 9,5, 10,7, 11,3, 12,4, 12,9, 15,6, 16,4, 16,8, 17,9, 19,0, 20,0, 20,9, 21,7, 22,4, 23,6, 25,2, 26,0, 26,7, 27,3, 28,2, 28,7, 29,6, 30,2, 30,9, 31,4, 32,2, 32,8 y 33,4 grados 2q en el difractograma de rayos X en polvo. Reivindicación 6: La sal de potasio cristalina de letermovir o el solvato de la misma de acuerdo con la reivindicación 4, en donde dicho solvato mixto de agua y etanol se caracteriza porque muestra picos característicos en aproximadamente 6,1, 9,4, 10,6, 11,2, 12,3, 12,8, 15,5, 16,3, 16,7, 17,8, 18,9, 19,9, 20,8, 21,7, 22,3, 23,5, 25,1, 25,9, 26,6, 27,1, 28,1, 28,5, 29,4, 30,1, 30,8, 31,2, 32,0, 32,6 y 33,3 grados 2q en el difractograma de rayos X en polvo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159742 | 2020-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121437A1 true AR121437A1 (es) | 2022-06-08 |
Family
ID=69742731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100495A AR121437A1 (es) | 2020-02-27 | 2021-02-26 | Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230150950A1 (es) |
| EP (1) | EP4110471A1 (es) |
| JP (1) | JP2023524349A (es) |
| KR (1) | KR20220148860A (es) |
| CN (1) | CN115427112A (es) |
| AR (1) | AR121437A1 (es) |
| AU (1) | AU2021227281A1 (es) |
| BR (1) | BR112022016890A2 (es) |
| CA (1) | CA3169075A1 (es) |
| CL (1) | CL2022002294A1 (es) |
| CO (1) | CO2022012006A2 (es) |
| CU (1) | CU20220046A7 (es) |
| EC (1) | ECSP22066666A (es) |
| IL (1) | IL295644A (es) |
| MX (1) | MX2022010442A (es) |
| PE (1) | PE20230512A1 (es) |
| TW (1) | TWI819279B (es) |
| UY (1) | UY39097A (es) |
| WO (1) | WO2021170882A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102005027517A1 (de) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
-
2021
- 2021-02-26 AR ARP210100495A patent/AR121437A1/es unknown
- 2021-02-26 UY UY0001039097A patent/UY39097A/es unknown
- 2021-03-01 AU AU2021227281A patent/AU2021227281A1/en active Pending
- 2021-03-01 JP JP2022551820A patent/JP2023524349A/ja active Pending
- 2021-03-01 CN CN202180016542.6A patent/CN115427112A/zh active Pending
- 2021-03-01 MX MX2022010442A patent/MX2022010442A/es unknown
- 2021-03-01 WO PCT/EP2021/055078 patent/WO2021170882A1/en unknown
- 2021-03-01 EP EP21708228.8A patent/EP4110471A1/en active Pending
- 2021-03-01 CA CA3169075A patent/CA3169075A1/en active Pending
- 2021-03-01 IL IL295644A patent/IL295644A/en unknown
- 2021-03-01 BR BR112022016890A patent/BR112022016890A2/pt unknown
- 2021-03-01 PE PE2022001803A patent/PE20230512A1/es unknown
- 2021-03-01 KR KR1020227033585A patent/KR20220148860A/ko unknown
- 2021-03-01 US US17/802,557 patent/US20230150950A1/en active Pending
- 2021-03-02 TW TW110107370A patent/TWI819279B/zh active
- 2021-03-02 CU CU2022000046A patent/CU20220046A7/es unknown
-
2022
- 2022-08-22 CL CL2022002294A patent/CL2022002294A1/es unknown
- 2022-08-23 CO CONC2022/0012006A patent/CO2022012006A2/es unknown
- 2022-08-24 EC ECSENADI202266666A patent/ECSP22066666A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022016890A2 (pt) | 2022-12-06 |
| CO2022012006A2 (es) | 2022-11-18 |
| CA3169075A1 (en) | 2021-09-02 |
| US20230150950A1 (en) | 2023-05-18 |
| KR20220148860A (ko) | 2022-11-07 |
| CL2022002294A1 (es) | 2023-02-03 |
| IL295644A (en) | 2022-10-01 |
| JP2023524349A (ja) | 2023-06-12 |
| UY39097A (es) | 2021-09-30 |
| PE20230512A1 (es) | 2023-03-24 |
| ECSP22066666A (es) | 2022-12-30 |
| WO2021170882A1 (en) | 2021-09-02 |
| TW202140455A (zh) | 2021-11-01 |
| TWI819279B (zh) | 2023-10-21 |
| CN115427112A (zh) | 2022-12-02 |
| AU2021227281A1 (en) | 2022-10-13 |
| CU20220046A7 (es) | 2023-04-10 |
| MX2022010442A (es) | 2022-10-18 |
| EP4110471A1 (en) | 2023-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2311200C2 (ru) | Комбинация ингибитора циклооксигеназы-2 и ингибитора гистондезацетилазы | |
| RU2486181C2 (ru) | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ | |
| PE20210405A1 (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteina con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| CY1119648T1 (el) | Αλατα και κρυσταλλικες μορφες παραγοντα που προκαλει αποπτωση | |
| HRP20160355T1 (hr) | Kristalni oblici 4-[5-[3-kloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida | |
| HRP20110359T1 (hr) | Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti | |
| HRP20231048T1 (hr) | Derivati bipirazola kao jak inhibitori | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| RU2014132884A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний | |
| ES2861503T3 (es) | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos | |
| PE20141148A1 (es) | Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| NO20053398L (no) | Farmasoytiske preparater av sertaconazol for vaginal anvendelse. | |
| GEP20125436B (en) | Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile | |
| BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
| AR007004A1 (es) | Sal de dihidrato de mesilato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona y composicionesfarmaceuticas que la contienen | |
| AR048899A1 (es) | Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros | |
| PE20220969A1 (es) | Sal | |
| RU2019111873A (ru) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм | |
| MX9203910A (es) | Derivados de acido 2-[3-(4-amidino-fenil)-propionico, su preparacion y su empleo. | |
| RU2367659C2 (ru) | Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) | |
| WO2014026039A4 (en) | Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways | |
| AR121437A1 (es) | Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético | |
| UY25310A1 (es) | Procedimiento para preparar un hidrato de la sal de ácido 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4 diona maleico | |
| AR058109A1 (es) | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie | |
| HRP20221230T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu |